Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
57.440USD
-1.070-1.83%
Close 11-02 16:00（ET）
11.12BMarket Cap
41.16P/E TTM
Today
-1.83%
5 Days
+3.03%
1 Month
+0.45%
6 Months
+6.25%
Year to Date
-3.35%
1 Year
+7.22%
Key Figures
58.660Open
59.510High
327.30KVolume
41.16P/E TTM
11.76P/E Dynamic
--Dividend TTM
0.17%Turnover Ratio
58.510Prev. Close
57.170Low
18.92MTurnover
26.04P/E Static
1.76P/B
0.00%Div Yield TTM
3.42%ROA
70.98052wk High
0.14Volume Ratio
426.86MNet Profit
193.57MShares
1.3951EPS TTM
0.22Beta
4.48%ROE
49.26052wk Low
3.85%Amplitude
70.25%Gross Margin
11.12BMarket Cap
7.31Reward/Risk
2.23%Risk Rate
BioMarin Pharmaceutical Inc's Score
0.01vs previous score
Forecast8.07
Financial Health8.89
Technical3.13
Valuation Dimensions7.72
Institutional Confidence10.00
Risk Assessment8.31
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
BioMarin Pharmaceutical Inc Technical Analysis
Technical Indicators
Neutral
Summary
Neutral
Moving Average
Neutral
BioMarin Pharmaceutical Inc Latest Earnings Call Transcripts
BioMarin (BMRN) Q3 2026 Earnings Call: Revenue Exceeds $1 Billion, Guidance Updated
BioMarin’s Q3 2026 earnings call covered revenue above $1 billion, 32% growth, updated 2026 guidance, VOXZOGO momentum and pipeline expansion.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.63/0.56
Revenue / Forecast
1.02B/1.03B
BioMarin Pharmaceutical Inc Profile
SectorPharmaceuticals
Ticker SymbolBMRN
Number of employees3040
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 8.41% |
| Dodge & Cox | 7.54% |
| PRIMECAP Management Company | 7.34% |
| Vanguard Capital Management, LLC | 4.47% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 44.20% |
| Investment Advisor/Hedge Fund | 35.63% |
| Hedge Fund | 10.24% |
| Sovereign Wealth Fund | 3.90% |
Related Instruments
-0.46%
-0.97%
-2.05%
-0.78%
+0.45%
-0.04%
-0.12%
-0.21%
+1.13%
+0.49%
-1.03%
+0.86%
+0.38%
+2.73%
+3.60%
-0.77%
-0.40%
-0.19%
+1.54%
-2.00%Popular Instruments
51839.500
-156.600 (-0.30%)
28205.800
+203.800 (+0.73%)
7557.300
+14.000 (+0.19%)
12797.000
-1.000 (-0.01%)
63291.000
+616.000 (+0.98%)
6191.200
+49.700 (+0.81%)
93.598
-1.688 (-1.77%)
338.320
-6.310 (-1.83%)
202.060
-2.580 (-1.26%)
3965.100
+19.320 (+0.49%)
FAQs
What is the current price of BioMarin Pharmaceutical Inc (BMRN)?
The current price of BioMarin Pharmaceutical Inc (BMRN) is 57.44.
What is the symbol of BioMarin Pharmaceutical Inc?
The ticker symbol of BioMarin Pharmaceutical Inc is BMRN.
What is the 52-week high of BioMarin Pharmaceutical Inc?
The 52-week high of BioMarin Pharmaceutical Inc is 70.98.
What is the 52-week low of BioMarin Pharmaceutical Inc?
The 52-week low of BioMarin Pharmaceutical Inc is 49.26.
What is the market capitalization of BioMarin Pharmaceutical Inc?
The market capitalization of BioMarin Pharmaceutical Inc is 11.12B.
Is BioMarin Pharmaceutical Inc (BMRN) currently rated as Buy, Hold, or Sell?
According to analysts, BioMarin Pharmaceutical Inc (BMRN) has an overall rating of Buy, with a price target of 91.54.
What is the Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN)?
The Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN) is 1.40.